OM2.F ORTHOFIX MED.INC. DL-10
- Market cap
- EUR 253M
- P/E
- -
- P/B
- 0.65x
- ROE
- -13.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OM2.F undervalued?
Graham numberThe Graham number of ORTHOFIX MED.INC. DL-10 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ORTHOFIX MED.INC. DL-10 fundamental analysis
No fundamental analysis for ORTHOFIX MED.INC. DL-10 yet.
ORTHOFIX MED.INC. DL-10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ORTHOFIX MED.INC. DL-10
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation impl…
Full company profileORTHOFIX MED.INC. DL-10 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ORTHOFIX MED.INC. DL-10 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 464M | 461M | 747M | 799M | 822M | 821M |
| Gross Profit | 350M | 337M | 486M | 546M | 566M | 581M |
| Operating Income | 1.37M | -28.9M | -142M | -77.7M | -82.6M | -24.0M |
| EBITDA | - | 15.7M | -79.5M | -18.3M | 9.93M | 29.5M |
| Net Income | -38.4M | -19.7M | -151M | -126M | -92.2M | -57.0M |
| EPS | -1.93 | -0.98 | -4.07 | -3.27 | -2.31 | -1.40 |
| Balance Sheet | ||||||
| Total Assets | 477M | 459M | 925M | 893M | 851M | 856M |
| Total Liabilities | 140M | 122M | 327M | 390M | 401M | 426M |
| Shareholders' Equity | 337M | 337M | 599M | 503M | 450M | 430M |
| Cash & Short-term Investments | 87.8M | 50.7M | 33.1M | 83.2M | 82.0M | 86.3M |
| Cash Flow | ||||||
| Operating Cash Flow | 18.5M | -11.5M | -45.8M | 25.8M | 33.3M | -31.3M |
| Capital Expenditure | 19.6M | 23.2M | 62.1M | 34.9M | 34.6M | 50.4M |
| Free Cash Flow | -1.12M | -34.7M | -108M | -9.09M | -1.28M | -81.7M |
| Ratios | ||||||
| ROE | -11.4% | -5.9% | -25.3% | -25.0% | -20.5% | -13.3% |
| ROA | -8.1% | -4.3% | -16.4% | -14.1% | -10.8% | -6.7% |
| Net Profit Margin | -8.3% | -4.3% | -20.3% | -15.8% | -11.2% | -7.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ORTHOFIX MED.INC. DL-10 dividends
ORTHOFIX MED.INC. DL-10 has not paid dividends in the last 5 fiscal years.
Who owns ORTHOFIX MED.INC. DL-10
- Insiders 2.17%
- Institutions 96.27%
- Public & others 1.56%
- Shares outstanding 40.8M
- Free float 40.4M
ORTHOFIX MED.INC. DL-10 company profile
- Company name
- ORTHOFIX MED.INC. DL-10
- Ticker
- OM2.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,605
- Fiscal year end
- December
- Address
- 3451 Plano Parkway, Lewisville, TX, United States, 75056
- Phone
- 214 937 2000
- Website
- orthofix.com
About ORTHOFIX MED.INC. DL-10
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graft substitutes, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers in various forms with supporting graft delivery solutions to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and 7D FLASH Navigation System, a navigation platform for spinal and cranial procedures. The Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market, including deformity correction, limb lengthening, complex fracture management, and limb preservation. This segment also designs, develops, and markets external and internal fixation limb reconstruction products that are coupled with enabling digital technologies to support the entire patient care continuum. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, healthcare providers, ambulatory surgery centers, and out-patient hospitals. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
ORTHOFIX MED.INC. DL-10 management
10- Mr. Massimo CalafiorePresident, CEO & Director · born 1972
- Ms. Julie B. AndrewsChief Financial Officer · born 1971
- Ms. Aviva McPherronPresident of Global Operations & Quality · born 1977
- Mr. J. Andres CedronChief Legal Officer & Corporate Secretary · born 1981
- Mr. Patrick FisherPresident of Global Biologics & Limb Reconstruction · born 1974
- Mr. Geoffrey C. GillespieChief Accounting Officer
- Ms. Julie D. DeweyChief Investor Relations & Communications Officer · born 1961
- Ms. Jill MasonChief Compliance & Risk Officer
- Ms. Stephanie WalshChief Human Resources Officer
- Dr. Beau Standish P.Eng., Ph.D.Chief Enabling Technologies Officer · born 1980